Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Executive Summary

FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.


Related Content

Gottlieb's Confirmation: Will Industry Ties Remain A Problem After The Hearing?
No More Sarepta-Like Development, FDA Officials Say
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows
Patients Can't Rescue Sarepta's Eteplirsen
FDA Orphan Designations At Record Levels; Resources Need To Keep Up
Sarepta's Eteplirsen Is Centerpiece Of Senate Hearing On Expanded Access
HHS Overrules FDA On Plan B OTC, Sends Teva Back To Drawing Board


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst